Related Experiment Video

Updated: Mar 30, 2026

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

9.6K

Safety and efficacy of targeted agents monotherapy in advanced NSCLC

Qi Zhang1,2, Yi-Long Wu2

  • 1a Graduate School , Southern Medical University , Guangzhou , Guangdong , PR China.

Expert Review of Clinical Pharmacology
|November 13, 2015
PubMed

Insights

Targeted therapy revolutionizes advanced non-small cell lung cancer (NSCLC) treatment. This review categorizes targeted agents by efficacy and targets, discussing their safety and effectiveness in monotherapy.

Area of Science:

  • Oncology
  • Pharmacology
  • Genetics

Background:

  • Targeted therapy has transformed advanced non-small cell lung cancer (NSCLC) treatment.
  • Numerous driver genes and targeted agents offer new therapeutic strategies for NSCLC.

Purpose of the Study:

  • To categorize targeted agents for NSCLC based on target clarity and therapeutic effects.
  • To review the latest clinical data on the safety and efficacy of monotherapy for three distinct categories of targeted agents.

Main Methods:

  • Literature review of clinical data.
  • Categorization of targeted agents into three groups: explicit targets/pure effects, theoretical targets/no biomarkers, vague targets/lower effects.
  • Analysis of safety and efficacy of monotherapy for each category.

Main Results:

  • Agents are classified based on target specificity and demonstrated efficacy.
  • Clinical data on monotherapy safety and effectiveness for each agent category will be presented.
  • The review highlights the evolving landscape of targeted therapies in NSCLC.

Conclusions:

  • The categorization provides a framework for understanding and selecting targeted agents in NSCLC.
  • Evidence-based review of monotherapy data informs clinical decision-making.
  • Advances in targeted therapy continue to improve outcomes for advanced NSCLC patients.
Keywords:
advanced NSCLCcheckpoint immune therapydriver genesmonotherapytargetted agents

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68